نبذة مختصرة : Background: Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs life and improves health-related quality of life (HRQoL) in this age group compared to conservative therapy, which has evolved considerably during the last decade.
Study Design: The Scandinavian Prostate Cancer Group (SPCG) 19/Norwegian Get-Randomized Research Group-Prostate (GRand-P) is a randomised, two-armed, controlled, multicentre, phase III trial carried out at study centres in Norway, Denmark, Finland, and Sweden.
Endpoints: The primary endpoints are overall survival and HRQoL (burden of disease scale, European Organisation for the Research and Treatment of Cancer [EORTC] Elderly Cancer patients). Secondary endpoints are PCa-specific survival, metastasis-free survival, role-functioning scale (EORTC quality of life questionnaire 30-item core), urinary irritative/obstructive scale (26-item Expanded Prostate Cancer Index Composite [EPIC-26]), bowel scale (EPIC-26), intervention-free survival, PCa morbidity, use of secondary and tertiary systemic therapies, mean quality-adjusted life-years (QALYs), and mean total healthcare costs.
Patients and Methods: A total of 980 men (aged ≥75 years) with non-metastatic, high-risk PCa will initially be screened with Geriatric 8 (G8) health status screening tool and Mini-COG© brief cognitive test. Participants identified by G8 as 'fit' or 'frail' will be randomised (ratio 1:1) to either immediate curative therapy (radiotherapy or prostatectomy) or conservative therapy (endocrine therapy or observation). Participants who are unable or unwilling to participate in randomisation will be enrolled in a separate observation group. Randomised patients will be followed for 10 years.
Trial Registration: Ethics approval has been granted in Norway (457593), Denmark (H-22051998), Finland (R23043) and Sweden (Dnr 2023-05296-01). The trial is registered on Clinicaltrials.org (NCT05448547).
(© 2024 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.)
References: Aas K, Dorothea Fosså S, Åge Myklebust T et al. Increased curative treatment is associated with decreased prostate cancer‐specific and overall mortality in senior adults with high‐risk prostate cancer; results from a national registry‐based cohort study. Cancer Med 2020; 9: 6646–6657.
Löffeler S, Halland A, Fawad H, Beisland C, Haug ES. Non‐metastatic prostate cancer: rationale for conservative treatment and impact on disease‐related morbidity and mortality in the elderly. Scand J Urol 2020; 54: 105–109.
Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol 2011; 60: 554–563.
Årsrapport 2022 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for prostatakreft. Oslo: Kreftregisteret, 2023.
Loffeler S, Halland A, Weedon‐Fekjaer H, Nikitenko A, Ellingsen CL, Haug ES. High Norwegian prostate cancer mortality: evidence of over‐reporting. Scand J Urol 2018; 52: 122–128.
Richstone L, Bianco FJ, Shah HH et al. Radical prostatectomy in men aged > or =70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int 2008; 101: 541–546.
Brassell SA, Rice KR, Parker PM et al. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. J Urol 2011; 185: 132–137.
Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease‐specific mortality. Cancer 2012; 118: 3062–3070.
Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011; 29: 235–241.
Bratt O, Folkvaljon Y, Hjalm Eriksson M et al. Undertreatment of men in their seventies with high‐risk nonmetastatic prostate cancer. Eur Urol 2015; 68: 53–58.
Yang DD, Mahal BA, Muralidhar V et al. Receipt of definitive therapy in elderly patients with unfavorable‐risk prostate cancer. Cancer 2017; 123: 4832–4840.
Årsrapport 2019 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for prostatakreft. Oslo: Kreftregisteret (Norwegian Cancer Registry), 2020.
Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population‐based cohort study. Ann Oncol 2018; 29: 377–385.
Bratt O, Carlsson S, Fransson P, Stranne J, Kindblom J. The Swedish national guidelines on prostate cancer, part I: early detection, diagnostics, staging, patient support and primary management of non‐metastatic disease. Scand J Urol 2022; 56: 265–273.
Bill‐Axelson A, Holmberg L, Garmo H et al. Radical prostatectomy or watchful waiting in prostate cancer – 29‐year follow‐up. N Engl J Med 2018; 379: 2319–2329.
Fosså SD, Wiklund F, Klepp O et al. Ten‐ and 15‐yr prostate cancer‐specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of The Scandinavian Prostate Cancer Group‐7. Eur Urol 2016; 70: 684–691.
Mulders PF, Molina A, Marberger M et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration‐resistant prostate cancer after docetaxel‐based chemotherapy. Eur Urol 2014; 65: 875–883.
Feng Z, Graff JN. Next‐generation androgen receptor‐signaling inhibitors for prostate cancer: considerations for older patients. Drugs Aging 2021; 38: 111–123.
Hofman CS, Makai P, Boter H et al. The influence of age on health valuations: the older olds prefer functional independence while the younger olds prefer less morbidity. Clin Interv Aging 2015; 10: 1131–1139.
Wedding U, Pientka L, Höffken K. Quality‐of‐life in elderly patients with cancer: a short review. Eur J Cancer 2007; 43: 2203–2210.
Seghers P, Wiersma A, Festen S et al. Patient preferences for treatment outcomes in oncology with a focus on the older patient‐a systematic review. Cancer 2022; 14: 1147.
Cherny NI, Dafni U, Bogaerts J et al. ESMO‐magnitude of clinical benefit scale version 1.1. Ann Oncol 2017; 28: 2340–2366.
Hamdy FC, Donovan JL, Lane JA et al. Fifteen‐year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023; 388: 1547–1558.
Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203–213.
Mason MD, Parulekar WR, Sydes MR et al. Final report of the intergroup randomized study of combined androgen‐deprivation therapy plus radiotherapy versus androgen‐deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 2015; 33: 2143–2150.
Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or without long‐term androgen suppression for prostate cancer with high metastatic risk: 10‐year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066–1073.
Droz JP, Albrand G, Gillessen S et al. Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol 2017; 72: 521–531.
Attard G, Murphy L, Clarke NW et al. Abiraterone acetate and prednisolone with or without enzalutamide for high‐risk non‐metastatic prostate cancer: a meta‐analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022; 399: 447–460.
Aghdam N, Pepin A, Carrasquilla M et al. Self‐reported burden in elderly patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT). Front Oncol 2019; 9: 1528.
Hamdy FC, Donovan JL, Lane JA et al. 10‐year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415–1424.
Warde P, Mason M, Ding K et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104–2111.
Pang HH, Wang X, Stinchcombe TE et al. Enrollment trends and disparity among patients with lung cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol 2016; 34: 3992–3999.
Sammon JD, Abdollah F, D'Amico A et al. Predicting life expectancy in men diagnosed with prostate cancer. Eur Urol 2015; 68: 756–765.
Wilson JR, Clarke MG, Ewings P, Graham JD, MacDonagh R. The assessment of patient life‐expectancy: how accurate are urologists and oncologists? BJU Int 2005; 95: 794–798.
Sheng W, Kirschner‐Hermanns R, Zhang H. Elderly patients aged >/= 75 years with locally advanced prostate cancer may benefit from local treatment: a population‐based propensity score‐adjusted analysis. World J Urol 2018; 37: 317–325.
Vatandoust S, Kichenadasse G, O'Callaghan M et al. Localised prostate cancer in elderly men aged 80‐89 years, findings from a population‐based registry. BJU Int 2018; 121(Suppl 3): 48–54.
Attard G, Parker C, Eeles RA et al. Prostate cancer. Lancet 2016; 387: 70–82.
Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of patient‐reported outcomes in routine medical care. Am Soc Clin Oncol Educ Book 2018; 38: 122–134.
Mierzynska J, Piccinin C, Pe M et al. Prognostic value of patient‐reported outcomes from international randomised clinical trials on cancer: a systematic review. Lancet Oncol 2019; 20: e685–e698.
Scotté F, Bossi P, Carola E et al. Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide. Ann Oncol 2018; 29: 1718–1726.
Droz JP, Balducci L, Bolla M et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010; 106: 462–469.
Cornford P, Bellmunt J, Bolla M et al. EAU‐ESTRO‐SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration‐resistant prostate cancer. Eur Urol 2017; 71: 630–642.
Mottet N, Bellmunt J, Bolla M et al. EAU‐ESTRO‐SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618–629.
Processing Request
No Comments.